Belantamab mafodotin in patients with severely impaired renal function: a phase I, 2-part study to evaluate pharmacokinetics, safety and efficacy in patients with relapsed/refractory multiple myeloma

S170at allo-HCT was complete response/very good partial response (n=18, 72%), partial response (PR) (n=6, 24%), and less than PR (n=1, 4%).Donor type distribution was as follows: MSD (n=12, 48%), MUD (n=7, 28%), and Haplo (n=6, 24%).Peripheral blood was the stem cell source in 23 (92%) patients.All patients engrafted.Cumulative incidence of acute GVHD grade II-IV and III-IV were 20% (95%CI, 38-70%) and 8% (1-23%), respectively.The 3-year cumulative incidence of NRM was 22% (95%CI: 3-52%) and of chronic GVHD 27% (95%CI: 11-47%).The 3-year OS, EFS, and GRFS were 74% (58-95%), 69% (52-91%), and 54% (37-79%), respectively.Conclusions: In this real-life cohort study, allo-HCT with the TBF conditioning regimen and GCHD prophylaxis with PTCy, sirolimus, and MMF showed encouraging results.It led to reduced acute and chronic GVHD incidence, improved GRFS, and favorable survival rates.These findings suggest that this combination holds promise as an effective treatment option for MM patients considered candidates for an allo-HCT.